Proceeds support advancement of two next-generation precision oncology programs into clinical development within 12 monthsFinancing led by Goldman Sachs Alternatives with participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investorsSAN DI...